Accessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

Decoding Salarius Pharmaceuticals’ Stock Movement

Ellis HobbsAvatar
Written by Ellis Hobbs Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 7/29/2025, 9:18 am ET | 6 min
Decoding Salarius Pharmaceuticals’ Stock Movement Thumbnail

In this article Last trade Aug, 25 1:29 PM

  • SLRX+0.12%
    SLRX - NASDAQSalarius Pharmaceuticals Inc.
    $5.78+0.01 (+0.12%)
    Volume:  39563
    Float:  503590
    $5.25Day Low/High$5.97

Salarius Pharmaceuticals Inc. stocks have been trading up by 128.04 percent following promising results and FDA endorsement.

  • An impending merger with Decoy Therapeutics promises strategic growth and could impact Salarius’ market perception.

  • Recent months have seen Salarius facing challenges such as non-compliance due to its stock price being below $1 for an extended period. Yet, regulatory extensions suggest room for recovery.

  • Despite hurdles, Salarius aims to fulfill Nasdaq’s equity requirements by early August in compliance with the financial rules, indicating a strategic plan amidst crisis.

  • Investors weigh Salarius’ prospects carefully as regulatory extensions and potential merger outcomes cause market speculation.

Candlestick Chart

Live Update At 09:18:11 EST: On Tuesday, July 29, 2025 Salarius Pharmaceuticals Inc. stock [NASDAQ: SLRX] is trending up by 128.04%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview: A Snapshot of Salarius

Trading can seem daunting without the right mindset and strategies. Success in penny stocks isn’t achieved overnight; it requires a keen understanding of market trends, dedication to learning, and a strategic approach. As millionaire penny stock trader and teacher Tim Sykes says, “Preparation plus patience leads to big profits.” This philosophy emphasizes the importance of thoroughly researching stocks and market conditions, and being patient for the right trading moment to manifest. Traders who grasp this concept frequently find themselves positioned for substantial gains, illustrating how critical preparation and patience are within the trading sphere.

The present financial scenario for Salarius Pharmaceuticals displays precarious navigation amidst stormy seas. The company faces losses as demonstrated by revenues diving to levels far below their historical performance, declining by 100% over three and five years respectively. With total equity below expectations and an enterprise value in the negative, the landscape seems challenging.

When we delve into profitability, notably absent are positive profit margins, while additional financial ratios indicate the company is swimming against a strong current. A pretax profit margin of -1,170% underlines such struggles. In light of these hurdles, shareholders remain wary yet alert to evolving circumstances.

Meanwhile, a precarious debt-to-equity ratio of 1.62 magnifies operational pressure, intersecting with an asset-to-turnover standing that calls for attention. An experientially low quick ratio, only a pinch ahead at 1.1, beckons strategic realignments to ensure liquidity in the face of adversity. Pair this with a three-tiered return on equity plummeting to -76.39%, showing inefficiency in capital use for delivering profits.

Noteworthy is the reported capital-flow adjustment. Reflecting a net cash outflow, the numbers suggest forthcoming challenges as the company juggles operating expenses with financing activities. Key aspects of the balance sheet reveal Salarius’ accrued liabilities surpassing assets, piling onto the pressing demand for responsible financial balancing acts.

Market Analysis: Unraveling Potential Outcomes

Nasdaq Extension and Market Response: The latest compliance extension by Nasdaq offers Salarius a temporary reprieve, allowing the company to align its financial strategy with strict equity standards, thus nurturing market confidence where uncertainty loomed. This extension shows faith in Salarius’ potential to rectify challenges, inducing cautious optimism among investors. Given the historical lows in share prices, this news may invigorate careful but hopeful trading, as market players recalibrate expectations that weigh Nasdaq’s conditional trust.

Merger Impact with Decoy Therapeutics: The alliance with Decoy Therapeutics offers promise but also calls for extra cautious consideration. The merger could yield the much-needed transformative growth. Yet, the path is riddled with uncertainties regarding whether this synergistic bond fares well enough to uplift Salarius beyond financial distress. Traders may remain divided, hedging bets on cooperation’s translation into tangible stock price movements.

Past Hurdles, Reactions and Forward Look: Bearish waves washed over Salarius when it failed to comply with Nasdaq’s minimum bid price. However, contingencies executed suggest strategic foresight potentially winning back investor support. Herein, traders may explore diversification within bio-pharma spaces, cautiously optimistic amidst potentially promising biotech advancements owing to, though undoubtedly steep, a pathway ahead.

More Breaking News

From Predictions to Reality: Navigating News Influence

As narratives emerge from Nasdaq extensions and merger intrigues, financial leaders remain attuned to ground realities, leading fact-fueled predictions on stock directions. In considering the news-led market craze, it’s crucial to differentiate emotion-driven anxiety from data-grounded projections. With a resolution expected in the early August horizon, traders face decisions while market winds stir. As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.” This advice is vital as traders navigate the uncertain landscape.

The situational assessment displays market volatility yet hints at potential recovery prospects. Looking forward, it’s the resolution of compliance challenges, merger solidification, and associated financial pivots that could reshape Salarius’ market destiny. As stories unfold, traders armed with patience and informed diligence await to witness if Salarius steadies rough seas or veers off course again.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Ellis Hobbs

Trainer and Mentor on Tim Sykes’ Trading Challenge
He teaches webinars on Tim Sykes’ Trading Challenge He treats trading like a business, not a hobby He emphasizes taking small risks — “If you get the process right, money is a forgone conclusion.”
Read More

In this article (YTD Performance)

  • SLRX-79.09%
    SLRX - NASDAQSalarius Pharmaceuticals Inc.
    $5.78+0.01 (+0.12%)
    Volume:  39563
    Float:  503590
    $5.25Day Low/High$5.97

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM
notification icon
Subscribe to receive notifications